Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies

2026-02-10 - 08:15

The investment demonstrates strong confidence in Kainova Therapeutics’ strategic direction and supports the clinical advancement of its GPCR-targeting therapies. Lead asset DT-7012, a Treg-depleting anti-CCR8 antibody, is progressing in the ongoing Phase I/II DOMISOL trial for the treatment of solid tumors. The Company is also advancing other GPCR-targeting therapies, including DT-9081, an EP4 antagonist for solid tumors and DT-9046, a small molecule biased antagonist of PAR2 for inflammatory conditions, further positioning Kainova Therapeutics as a leader in global precision medicine. Read More